• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3: New insider Guzman Pablo A. claimed ownership of 26,021 shares

    1/26/23 8:22:23 PM ET
    $LSPR
    Consumer Electronics/Appliances
    Industrials
    Get the next $LSPR alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Guzman Pablo A.

    (Last) (First) (Middle)
    C/O ZYVERSA THERAPEUTICS, INC.
    2200 N. COMMERCE PARKWAY, SUITE 208

    (Street)
    WESTON FL 33326

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    01/26/2023
    3. Issuer Name and Ticker or Trading Symbol
    ZyVersa Therapeutics, Inc. [ ZVSA ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Medical Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 26,021 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) 01/15/2015 01/14/2025 Common Stock 2,978 5.03 D
    Stock Option (Right to Buy) (1) 04/08/2025 Common Stock 9,927 5.03 D
    Stock Option (Right to Buy) (2) 04/01/2029 Common Stock 19,854 11.58 D
    Stock Option (Right to Buy) 10/31/2020 10/31/2030 Common Stock 11,019 16.36 D
    Stock Option (Right to Buy) 12/31/2020 12/31/2030 Common Stock 2,912 16.36 D
    Stock Option (Right to Buy) 03/31/2021 03/31/2031 Common Stock 4,368 16.36 D
    Stock Option (Right to Buy) 06/30/2021 06/30/2031 Common Stock 4,368 16.36 D
    Stock Option (Right to Buy) 09/30/2021 09/30/2031 Common Stock 4,368 16.36 D
    Stock Option (Right to Buy) 12/31/2021 12/31/2031 Common Stock 4,368 16.36 D
    Stock Option (Right to Buy) 03/31/2022 03/31/2032 Common Stock 4,368 16.36 D
    Stock Option (Right to Buy) 06/30/2022 06/30/2032 Common Stock 4,368 11.33 D
    Warrant (Right to Buy) 12/12/2022 12/12/2027 Common Stock 9,015 6.9 D
    Explanation of Responses:
    1. 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on January 22, 2016.
    2. 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 1, 2020.
    Remarks:
    Exhibit 24- Power of Attorney
    /s/ Pablo Guzman 01/26/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LSPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LSPR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LSPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022 (Ticker "ZVSA")

    ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product candidates for treatment of renal and inflammatory diseases WESTON, Fla. and BRIDGEWATER, N.J., Dec. 12, 2022 /PRNewswire/ -- ZyVersa Therapeutics, Inc. ("ZyVersa"), a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop products for patients with renal or inflammatory diseases with high unmet medical needs, and Larkspur Health Acquisition Corp. (NASDAQ:LSPR, Larkspur", ))), a blank-check special purpose acquisition company, are pleased to announce closing of their previously announced business combination.

    12/12/22 9:05:00 PM ET
    $LSPR
    Consumer Electronics/Appliances
    Industrials

    ZyVersa Therapeutics' CEO, Stephen C. Glover, and CCO, Karen A. Cashmere, Are Invited Speakers at the 4th Inflammasome Therapeutics Summit

    Annual Inflammasome Summit unites world renowned experts in inflammasome-targeted drug development and academia to share information and address knowledge gaps in this rapidly evolving fieldZyVersa is well positioned in the emerging inflammasome space with a highly differentiated inflammasome ASC inhibitor (IC 100), which has potential to treat a broad range of inflammatory diseasesBy inhibiting ASC, IC 100 inhibits multiple types of inflammasomes, not just NLRP3, to stop initiation of the inflammatory cascade and progression of damaging inflammation that is pathogenic in inflammatory diseasesZyVersa and Larkspur Health entered into a definitive business combination agreement on July 20, 202

    11/22/22 7:05:00 AM ET
    $LSPR
    Consumer Electronics/Appliances
    Industrials

    SEC Declares Form S-4 Registration Statement "Effective" for Proposed Business Combination of Larkspur Health Acquisition Corp., Inc. with ZyVersa Therapeutics, Inc.

    Special meeting of Larkspur stockholders scheduled for December 8, 2022, to vote on the proposed business combination of Larkspur with ZyVersaZyVersa is a clinical stage biopharmaceutical company with two licensed proprietary product platforms, a cholesterol efflux mediator targeting multiple renal diseases, and an inflammatory ASC inhibitor targeting numerous inflammatory diseasesZyVersa and Larkspur Health entered into a definitive business combination agreement dated July 20, 2022, as amended (the "Business Combination Agreement") Combined company expected to be named ZyVersa Therapeutics, Inc. and listed on NASDAQ in fourth quarter of 2022 under ticker "ZVSA"BRIDGEWATER, N.J. and WESTON,

    11/15/22 7:05:00 AM ET
    $LSPR
    Consumer Electronics/Appliances
    Industrials

    $LSPR
    SEC Filings

    View All

    SEC Form S-8 filed by Larkspur Health Acquisition Corp.

    S-8 - ZyVersa Therapeutics, Inc. (0001859007) (Filer)

    2/14/24 4:34:51 PM ET
    $LSPR
    Consumer Electronics/Appliances
    Industrials

    Larkspur Health Acquisition Corp. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - ZyVersa Therapeutics, Inc. (0001859007) (Filer)

    12/22/23 4:45:17 PM ET
    $LSPR
    Consumer Electronics/Appliances
    Industrials

    Larkspur Health Acquisition Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ZyVersa Therapeutics, Inc. (0001859007) (Filer)

    12/11/23 4:30:44 PM ET
    $LSPR
    Consumer Electronics/Appliances
    Industrials

    $LSPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Incon Co., Ltd.

    4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)

    8/3/23 7:49:35 AM ET
    $LSPR
    Consumer Electronics/Appliances
    Industrials

    SEC Form 4 filed by Guzman Pablo A.

    4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)

    1/26/23 8:25:12 PM ET
    $LSPR
    Consumer Electronics/Appliances
    Industrials

    SEC Form 3: New insider Guzman Pablo A. claimed ownership of 26,021 shares

    3 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)

    1/26/23 8:22:23 PM ET
    $LSPR
    Consumer Electronics/Appliances
    Industrials

    $LSPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Larkspur Health Acquisition Corp. (Amendment)

    SC 13G/A - ZyVersa Therapeutics, Inc. (0001859007) (Subject)

    2/14/24 6:09:37 PM ET
    $LSPR
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G filed by Larkspur Health Acquisition Corp.

    SC 13G - ZyVersa Therapeutics, Inc. (0001859007) (Subject)

    2/14/24 4:12:56 PM ET
    $LSPR
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G/A filed by Larkspur Health Acquisition Corp. (Amendment)

    SC 13G/A - ZyVersa Therapeutics, Inc. (0001859007) (Subject)

    2/9/24 4:04:05 PM ET
    $LSPR
    Consumer Electronics/Appliances
    Industrials